BAD HOMBURG, Germany--(BUSINESS WIRE)--Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation..

德国巴德洪堡——（商业新闻短讯）——费森尤斯今天通过其运营公司费森尤斯·卡比（Fresenius Kabi）宣布，美国将立即推出Tyenne®（tocilizumab aazg），一种Actemra®（tocilizumab）的生物仿制药。Tyenne®用于治疗慢性自身免疫性疾病，可通过静脉注射（IV）制剂获得。。

Michael Sen, CEO of Fresenius: “With the launch of Tyenne® in the U.S., we have reached another important milestone in accelerating our strong (Bio)Pharma momentum. Growing this platform is a substantial cornerstone of our #FutureFresenius journey. Overall, we have seen an excellent performance of our (Bio)Pharma business in 2024 so far.

费森尤斯（Fresenius）首席执行官迈克尔·森（Michael Sen）：“随着Tyenne®在美国的推出，我们在加速强大的（生物）制药势头方面达到了另一个重要里程碑。发展这个平台是我们未来费森尤斯之旅的重要基石。总的来说，到目前为止，我们的（生物）制药业务在2024年取得了出色的表现。

We are particularly happy with the good progress of our majority-owned biotechnology company mAbxience and the traction of Tyenne®, the first tocilizumab biosimilar available in Europe since November 2023.”.

我们对我们控股的生物技术公司mAbxience的良好进展以及自2023年11月以来在欧洲推出的第一种托珠单抗生物仿制药Tyenne®的牵引力感到特别高兴。”。

Tyenne® is the first tocilizumab biosimilar with an intravenous and subcutaneous formulation approved by the FDA. The biosimilar received FDA approval on March 5, 2024. Tyenne® is Fresenius’ third approved biosimilar available in the U.S. and the second within its immunology portfolio. The biologic medicine is indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis..

Tyenne®是FDA批准的第一种具有静脉和皮下制剂的托珠单抗生物仿制药。该生物仿制药于2024年3月5日获得FDA批准。Tyenne®是Fresenius在美国提供的第三种经批准的生物仿制药，也是其免疫学产品组合中的第二种。该生物药物适用于治疗几种自身免疫性疾病，包括类风湿性关节炎，巨细胞动脉炎，多关节幼年特发性关节炎和全身性幼年特发性关节炎。。

Pierluigi Antonelli, CEO of Fresenius Kabi: “Tyenne® will impact the treatment landscape for inflammatory and immune diseases in the U.S. Reaching ever more patients with our state-of-the-art biopharma portfolio signals a clear growth path in a highly promising market segment. We will continue to roll out our comprehensive pipeline of autoimmune and oncology biosimilars with several molecules in late-stage development.”.

费森尤斯·卡比（Fresenius Kabi）首席执行官皮尔路易吉·安东内利（Pierluigi Antonelli）：“Tyenne®将影响美国炎症和免疫疾病的治疗前景。通过我们最先进的生物制药组合，让更多的患者受益，标志着我们在一个极具前景的细分市场中有了明确的增长道路。我们将继续推出我们的综合性自身免疫和肿瘤生物仿制药产品线，其中包括几个处于后期开发阶段的分子。”。

Supported by Fresenius Kabi’s support program for health care professionals and patients, the company’s biologic medicine provides wider access to more treatment options and contributes to the viability of health care systems.

在费森尤斯·卡比（Fresenius Kabi）针对医疗保健专业人员和患者的支持计划的支持下，该公司的生物医药为更多的治疗选择提供了更广泛的途径，并有助于医疗保健系统的生存。

Next to its two available biosimilars, Idacio® (adalimumab) and Stimufend® (pegfilgrastim), Fresenius Kabi has a growing pipeline of autoimmune and oncology biosimilars with several molecules in late-stage development.

除了两种可用的生物仿制药Idacio®（阿达木单抗）和Stimufend®（pegfilgrastim）之外，费森尤斯·卡比还有不断增长的自身免疫和肿瘤学生物仿制药管道，其中有几种分子处于后期开发阶段。

To learn more about how Fresenius Kabi provides comprehensive patient support for Tyenne® in the U.S. please click here.

要了解更多有关费森尤斯·卡比（Fresenius Kabi）如何在美国为Tyenne®提供全面的患者支持的信息，请单击此处。

With #FutureFresenius, Fresenius successfully set the course last year to become a leading therapy-focused company. In line with the strategy, Fresenius has simplified its structure, is sharpening its focus by concentrating on its operating companies Fresenius Kabi and Fresenius Helios and is continuously enhancing its performance..

凭借#FutureFresenius，Fresenius去年成功地确立了成为领先的以治疗为重点的公司的道路。根据该战略，费森尤斯简化了结构，通过专注于其运营公司费森尤斯·卡比（Fresenius Kabi）和费森尤斯·赫利俄斯（Fresenius Helios）来加强重点，并不断提高其业绩。。

About Tyenne®, a Tocilizumab Biosimilar

关于托珠单抗生物仿制药Tyenne®

Tyenne® (tocilizumab-aazg), a biosimilar to Actemra® (tocilizumab), is a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. It was developed by Fresenius Kabi using advanced analytical and manufacturing technologies for use in the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Tyenne®（tocilizumab aazg）是Actemra®（tocilizumab）的生物仿制药，是一种称为白细胞介素-6（IL-6）受体拮抗剂的处方药。它是由Fresenius Kabi使用先进的分析和制造技术开发的，用于治疗几种自身免疫性疾病，包括类风湿性关节炎，巨细胞动脉炎，多关节幼年特发性关节炎和全身性幼年特发性关节炎。

Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic infections have occurred in patients receiving the product. Tyenne is contraindicated in patients with known hypersensitivity to tocilizumab products. For more information about Tyenne, please see the full prescribing information for the U.S.

接受该产品的患者发生了导致住院或死亡的严重感染，包括结核病（TB），细菌，侵袭性真菌，病毒和其他机会性感染。Tyenne在已知对托珠单抗产品过敏的患者中是禁忌的。有关Tyenne的更多信息，请参阅美国的完整处方信息。

here..

这里。。

IMPORTANT SAFETY INFORMATION

重要安全信息

RISK OF SERIOUS INFECTIONS

严重感染的风险

Patients treated with TYENNE® (tocilizumab-aazg) are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt TYENNE until the infection is controlled..

接受TYENNE®（托珠单抗aazg）治疗的患者发生严重感染的风险增加，可能导致住院或死亡，包括结核病（TB），细菌，侵袭性真菌，病毒或其他机会性感染。如果发生严重感染，中断TYENNE直到感染得到控制。。

Reported infections include:

报告的感染包括：

Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before TYENNE use and during therapy. Treatment for latent infection should be initiated prior to TYENNE use.

活动性结核病，可能伴有肺部或肺外疾病。患者应在使用泰恩之前和治疗期间进行潜伏性结核病检测。潜伏感染的治疗应在使用泰恩之前开始。

Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.

侵袭性真菌感染，包括念珠菌病，曲霉病和肺孢子虫病。侵袭性真菌感染患者可能会出现播散性疾病，而不是局限性疾病。

Bacterial, viral and other infections due to opportunistic pathogens.

由机会性病原体引起的细菌、病毒和其他感染。

The risks and benefits of treatment with TYENNE should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

在慢性或复发性感染患者开始治疗之前，应仔细考虑泰恩治疗的风险和益处。

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with TYENNE, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

应密切监测患者在泰恩治疗期间和治疗后感染体征和症状的发展，包括在开始治疗前潜伏性结核感染检测为阴性的患者可能发展为结核病。

CONTRAINDICATION

禁忌症

TYENNE is contraindicated in patients with known hypersensitivity to tocilizumab products.

TYENNE在已知对托珠单抗产品过敏的患者中是禁忌的。

WARNINGS AND PRECAUTIONS

警告和注意事项

Gastrointestinal Perforations

胃肠穿孔

Events of gastrointestinal (GI) perforation have been reported in clinical trials, primarily as complications of diverticulitis in patients treated with tocilizumab. Use TYENNE with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with new-onset abdominal symptoms for early identification of GI perforation..

临床试验报道了胃肠道（GI）穿孔事件，主要是托珠单抗治疗患者憩室炎的并发症。对于胃肠道穿孔风险可能增加的患者，请谨慎使用泰恩。及时评估出现新发腹部症状的患者，以早期发现胃肠道穿孔。。

Hepatotoxicity

肝毒性

Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous tocilizumab products. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation. Most cases presented with marked elevations of transaminases (> 5 times ULN), and some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases..

在服用静脉或皮下托珠单抗产品的患者中观察到严重的肝损伤病例。其中一些病例已导致肝移植或死亡。开始治疗后，病例的发病时间从几个月到几年不等。大多数病例表现出明显的转氨酶升高（>5倍ULN），有些病例表现出肝功能障碍的体征或症状，只有轻度转氨酶升高。。

Treatment with tocilizumab was associated with a higher incidence of transaminase elevations; increased frequency and magnitude of these elevations were observed when tocilizumab was used in combination with potentially hepatotoxic drugs (e.g., methotrexate).

托珠单抗治疗与转氨酶升高的发生率较高有关；当托珠单抗与潜在的肝毒性药物（例如甲氨蝶呤）联合使用时，观察到这些升高的频率和幅度增加。

It is not recommended to initiate TYENNE treatment in RA, GCA, PJIA, and SJIA patients with elevated transaminases ALT or AST greater than 1.5x ULN. In patients who develop elevated ALT or AST greater than 5x ULN discontinue TYENNE.

不建议对转氨酶ALT或AST升高超过1.5倍ULN的RA，GCA，PJIA和SJIA患者开始TYENNE治疗。对于ALT或AST升高超过5倍ULN的患者，停止使用TYENNE。

Measure liver tests promptly in patients who report symptoms that may indicate liver injury. If the patient is found to have abnormal liver tests, TYENNE treatment should be interrupted. TYENNE should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests..

报告可能表明肝损伤症状的患者应立即进行肝脏检查。如果发现患者肝脏检查异常，应中断泰恩治疗。只有在肝脏检查正常化后，对肝脏检查异常有另一种解释的患者才能重新开始TYENNE。。

Laboratory Parameters

实验室参数

Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Dosage modifications may be required.

由于中性粒细胞，血小板，脂质和肝功能检查中与治疗相关的实验室异常的潜在后果，建议进行实验室监测。可能需要修改剂量。

Neutropenia: Treatment with tocilizumab products was associated with a higher incidence of neutropenia. It is not recommended to initiate TYENNE treatment in RA, GCA, PJIA, and SJIA patients with a low neutrophil count i.e., absolute neutrophil count (ANC) less than 2000 per mm3. In patients who develop an ANC less than 500 per mm3 treatment is not recommended..

中性粒细胞减少症：用托珠单抗产品治疗与中性粒细胞减少症的发生率较高有关。不建议在中性粒细胞计数低的RA，GCA，PJIA和SJIA患者中开始TYENNE治疗，即绝对中性粒细胞计数（ANC）小于2000/mm3。对于ANC低于每mm3 500的患者，不建议进行治疗。。

Thrombocytopenia: Treatment with tocilizumab products was associated with a reduction in platelet counts. It is not recommended to initiate TYENNE in RA, GCA, PJIA, and SJIA patients with a platelet count below 100,000 per mm3. In patients who develop a platelet count less than 50,000 per mm3, treatment is not recommended..

血小板减少症：用托珠单抗产品治疗与血小板计数减少有关。不建议在血小板计数低于100000/mm3的RA，GCA，PJIA和SJIA患者中启动TYENNE。对于血小板计数低于50000/mm3的患者，不建议进行治疗。。

Elevated Liver Enzymes: It is not recommended to initiate TYENNE treatment in patients with elevated transaminases ALT or AST >1.5x ULN. In patients who develop elevated ALT or AST >5x ULN, treatment is not recommended.

肝酶升高：对于转氨酶ALT或AST升高>1.5倍ULN的患者，不建议开始TYENNE治疗。对于ALT或AST升高>5倍ULN的患者，不建议进行治疗。

Lipid Abnormalities: Treatment with tocilizumab products was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterols, and/or HDL cholesterol.

脂质异常：用托珠单抗产品治疗与总胆固醇，甘油三酯，LDL胆固醇和/或HDL胆固醇等脂质参数的增加有关。

Immunosuppression

免疫抑制

The impact of treatment with tocilizumab products on the development of malignancies is not known, but malignancies were observed in clinical studies with tocilizumab. TYENNE is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.

托珠单抗产品治疗对恶性肿瘤发展的影响尚不清楚，但在托珠单抗的临床研究中观察到恶性肿瘤。泰恩是一种免疫抑制剂，用免疫抑制剂治疗可能会增加恶性肿瘤的风险。

Hypersensitivity Reactions

超敏反应

Hypersensitivity reactions, including anaphylaxis, have been reported in association with tocilizumab products and anaphylactic events with a fatal outcome have been reported with intravenous infusion of tocilizumab products. TYENNE for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis.

已经报道了与托珠单抗产品相关的超敏反应，包括过敏反应，并且已经报道了静脉输注托珠单抗产品导致致命结果的过敏事件。静脉注射泰恩只能由医疗保健专业人员在适当的医疗支持下注入，以管理过敏反应。

For TYENNE subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of TYENNE immediately and discontinue TYENNE permanently. Do not administer TYENNE to patients with known hypersensitivity to tocilizumab products..

对于TYENNE皮下注射，如果患者出现任何过敏反应症状，建议患者立即就医。如果发生过敏反应或其他超敏反应，立即停止服用泰恩，并永久停用泰恩。不要给已知对托珠单抗产品过敏的患者服用泰恩。。

Demyelinating Disorders

脱髓鞘性疾病

The impact of treatment with tocilizumab products on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Monitor patients for signs and symptoms of demyelinating disorders. Prescribers should exercise caution in considering the use of TYENNE in patients with preexisting or recent onset demyelinating disorders..

托珠单抗产品治疗脱髓鞘疾病的影响尚不清楚，但临床研究中很少报道多发性硬化症和慢性炎性脱髓鞘性多发性神经病。监测患者脱髓鞘疾病的体征和症状。处方者应谨慎考虑在先前存在或近期发作的脱髓鞘疾病患者中使用泰恩。。

Active Hepatic Disease and Hepatic Impairment

活动性肝病与肝功能损害

Treatment with TYENNE is not recommended in patients with active hepatic disease or hepatic impairment.

活动性肝病或肝功能损害患者不建议使用泰恩治疗。

Vaccinations

接种疫苗

Avoid use of live vaccines concurrently with TYENNE. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving TYENNE or on the effectiveness of vaccination in patients receiving TYENNE. Patients should be brought up to date on all recommended vaccinations prior to initiation of TYENNE therapy, if possible..

避免与泰恩同时使用活疫苗。没有关于接受活疫苗的人向接受TYENNE的患者继发感染的数据，也没有关于接受TYENNE的患者接种疫苗的有效性的数据。如果可能的话，在开始泰恩疗法之前，应向患者介绍所有推荐疫苗的最新情况。。

ADVERSE REACTIONS

不良反应

Most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions.

最常见的不良反应（发生率至少为5%）：上呼吸道感染，鼻咽炎，头痛，高血压，ALT升高，注射部位反应。

DRUG INTERACTIONS

药物相互作用

In GCA patients, no effect of concomitant corticosteroid on tocilizumab exposure was observed.

在GCA患者中，未观察到伴随皮质类固醇对托珠单抗暴露的影响。

Cytochrome P450s in the liver are down-regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in RA patients treated with tocilizumab products may restore CYP450 activities to higher levels than those in the absence of tocilizumab products leading to increased metabolism of drugs that are CYP450 substrates..

肝脏中的细胞色素P450被感染和炎症刺激（包括细胞因子如IL-6）下调。在用托珠单抗产品治疗的RA患者中抑制IL-6信号传导可以将CYP450活性恢复到比不存在托珠单抗产品时更高的水平，从而导致作为CYP450底物的药物代谢增加。。

Exercise caution when coadministering TYENNE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.

当泰恩与CYP3A4底物药物共同给药时，如果不希望有效性降低，请谨慎使用，例如口服避孕药，洛伐他汀，阿托伐他汀等。

USE IN PREGNANCY

怀孕期间使用

The limited available data with tocilizumab products in pregnant women are not sufficient to determine whether there is a drug-associated risk for major birth defects and miscarriage.

孕妇中托珠单抗产品的有限可用数据不足以确定是否存在与药物相关的重大出生缺陷和流产风险。

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Fresenius Kabi at (800) 551-7176.

您可以通过（800）FDA-1088或www.FDA.gov/medwatch向FDA报告副作用。您也可以致电（800）551-7176向费森尤斯·卡比报告副作用。

Please see additional Important Safety Information in full Prescribing Information, including Boxed Warning.

请参阅完整处方信息中的其他重要安全信息，包括盒装警告。

INDICATIONS

适应症

TYENNE is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

TYENNE适用于治疗对一种或多种疾病缓解抗风湿药物（DMARDs）反应不足的中度至重度活动性类风湿性关节炎（RA）成年患者。

TYENNE is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

TYENNE适用于治疗成年患者的巨细胞动脉炎（GCA）。

TYENNE is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

TYENNE适用于治疗2岁及以上患者的活动性多关节幼年特发性关节炎（PJIA）。

TYENNE is indicated for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.

TYENNE适用于治疗2岁及以上患者的活动性全身性幼年特发性关节炎（SJIA）。

Tyenne® demonstrates Fresenius Kabi’s commitment to providing access to affordable and cost-effective biosimilars to more patients living with autoimmune diseases around the world while enabling savings for health care systems. KabiCare, Fresenius Kabi’s comprehensive patient support program, will be available to patients and health care providers in the U.S.

Tyenne®证明了费森尤斯·卡比（Fresenius Kabi）致力于为世界各地更多患有自身免疫性疾病的患者提供负担得起且具有成本效益的生物仿制药，同时为医疗保健系统节省开支。费森尤斯·卡比（Fresenius Kabi）的综合患者支持计划KabiCare将向美国的患者和医疗保健提供者提供。

from launch..

从发布。。

About Fresenius SE

关于费森尤斯SE

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue with its more than 190,000 employees. Fresenius offers solutions to the social challenges posed by a growing and ageing population and the resulting need for affordable, high-quality healthcare.

Fresenius SE&Co.KGaA（法兰克福/塞特拉：法国）是一家全球医疗保健公司，总部位于德国巴德洪堡v.d.Höhe。在2023财政年度，费森尤斯拥有19万多名员工，年收入223亿欧元。费森尤斯为人口增长和老龄化带来的社会挑战以及由此产生的对负担得起的高质量医疗保健的需求提供了解决方案。

The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment companies Fresenius Vamed and Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year.

费森尤斯集团由运营公司费森尤斯·卡比（Fresenius Kabi）和费森尤斯·赫利奥斯（Fresenius Helios）以及投资公司费森尤斯·瓦梅德（Fresenius Vamed）和费森尤斯医疗（Fresenius Medical Care）组成。费森尤斯·赫利奥斯拥有140家医院和无数的门诊设施，是德国和西班牙领先的私立医院运营商，每年治疗约2600万患者。

Fresenius Kabi’s product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952.

费森尤斯·卡比的产品组合包括一系列高度复杂的生物制药、临床营养、医疗技术和仿制药。费森尤斯于1912年由法兰克福药剂师爱德华·费森尤斯博士创立。Else Kröner去世后，于1952年接管公司管理层。

She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects..

她为今天追求改善人民健康目标的全球企业奠定了基础。最大股东是非营利性Else Kröner Fresenius基金会，该基金会致力于推进医学研究和支持人道主义项目。。

For more information visit the company website at www.fresenius.com.

有关更多信息，请访问公司网站www.fresenius.com。

Follow us on social media: www.fresenius.com/socialmedia.

在社交媒体上关注我们：www.fresenius.com/socialmedia。

About Fresenius Kabi

关于费森尤斯·卡比

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.

费森尤斯·卡比（Fresenius Kabi）是一家全球医疗保健公司，专门从事输液、输血和临床营养方面的救生药物和技术。该公司的产品和服务用于危重病和慢性病患者的治疗和护理。

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products.

其产品组合包括一系列高度复杂的生物制药、临床营养、医疗技术和静脉注射仿制药。在生物制药领域，费森尤斯·卡比（Fresenius Kabi）除其他外，还提供专注于自身免疫性疾病和肿瘤学的生物仿制药。该公司的临床营养产品包括多种肠内和肠外营养产品。

In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face..

在医疗技术领域，其产品包括重要的一次性用品、输液泵、单采机、细胞治疗设备等。费森尤斯·卡比（Fresenius Kabi）将基本药物和技术交给了那些帮助患者并为他们面临的挑战找到最佳答案的人。。

Following its strategy “Vision 2026”, which is a key part of the #FutureFresenius program of the Fresenius healthcare group, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders..

根据其战略“2026年愿景”，这是费森尤斯医疗集团未来费森尤斯计划的关键部分，该公司还致力于提高患者治疗和护理的效率，并改善全球优质医疗服务的获得。费森尤斯·卡比（Fresenius Kabi）希望在其产品领域处于全球领先地位，这一切都是为了患者、客户和利益相关者的利益。。

Actemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.

Actemra®是罗氏集团成员Chugai Seiyaku Kabushiki Kaisha Corp.的注册商标。

Tyenne® is a registered trademark of Fresenius Kabi Deutschland GmbH.

Tyenne®是Fresenius Kabi Deutschland GmbH的注册商标。

Idacio® and Stimufend® are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries.

Idacio®和Stimufend®是Fresenius Kabi Deutschland GmbH在选定国家的注册商标。